Ignite Creation Date:
2024-05-05 @ 7:43 PM
Last Modification Date:
2024-10-26 @ 9:53 AM
Study NCT ID:
NCT00725764
Status:
COMPLETED
Last Update Posted:
2017-10-16
First Post:
2008-07-28
Brief Title:
Phase 2 Study of GSK1363089 Formerly XL880 in Adults With Squamous Cell Cancer of the Head and Neck
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase 2 Study of the MET RTK Inhibitor GSK1363089 Formerly XL880 in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being conducted to determine the best confirmed response rate safety and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck SCCHN GSK1363089 is a new chemical entity that inhibits multiple receptor tyrosine kinases RTKs with growth-promoting and angiogenic properties The primary targets of GSK1363089 are the HGF and vascular endothelial growth factor VEGF RTK families eg MET VEGFR2kinase insert domain receptor KDR Since MET overexpression has been associated with poorer prognosis and MET tyrosine kinase mutations have been reported in SCCHN inhibition of MET receptor and VEGFR2KDR activation by agents such as GSK1363089 may be of therapeutic benefit in this patient population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None